Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H22N4O23P4.4Na |
| Molecular Weight | 878.2344 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[Na+].[Na+].O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N3C=CC(=O)NC3=O)N4C=CC(=O)NC4=O
InChI
InChIKey=OWTGMPPCCUSXIP-FNXFGIETSA-J
InChI=1S/C18H26N4O23P4.4Na/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30;;;;/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30);;;;/q;4*+1/p-4/t7-,8-,11-,12-,13-,14-,15-,16-;;;;/m1..../s1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C18H22N4O23P4 |
| Molecular Weight | 786.2753 |
| Charge | -4 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including http://www.santeninc.com/newsroom/press-releases/10_04_DIQUAS.pdf | http://www.santen.com/en/therapeutic-areas/asia/dryeye/diquas/
Curator's Comment: Description was created based on several sources, including http://www.santeninc.com/newsroom/press-releases/10_04_DIQUAS.pdf | http://www.santen.com/en/therapeutic-areas/asia/dryeye/diquas/
Diquafosol, a dinucleotide Up4U, is an agonist for purinergic P2Y2 receptor. Diquafosol stimulated water and mucin secretion by acting on P2Y2 receptors on the conjunctival epithelial and goblet cell membrane and elevating intracellular calcium ion concentrations. The Japanese Ministry of Health, Labour and Welfare granted approval for DIQUAS Ophthalmic Solution 3% (diquafosol tetrasodium) for the treatment of dry eye.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4398 |
0.1 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | DIQUAS Approved UseDIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium) should be used in patients diagnosed with dry eye, associated with keratoconjunctival epithelium disorders that accompany lacrimal fluid abnormality. Launch Date1.27128961E12 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. | 2001 Jan |
|
| Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease. | 2002 |
|
| Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits. | 2002 |
|
| Metabolism and transport of purinergic receptor agonists in rabbit conjunctival epithelial cells. | 2002 |
|
| INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. | 2002 Aug |
|
| Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease. | 2002 Dec 5 |
|
| Novel noninvasive sensitive determination of tear volume changes in normal cats. | 2002 Nov-Dec |
|
| Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. | 2002 Sep |
|
| Diquafosol: DE 089, diquafosol tetrasodium, INS 365, INS 365 Ophthalmic, INS 365 Respiratory, KPY 998. | 2003 |
|
| Selective P2Y2 receptor agonists stimulate vaginal moisture in ovariectomized rabbits. | 2003 Feb |
|
| Diquafosol tetrasodium. Inspire/Allergan/Santen. | 2003 Nov |
|
| Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. | 2004 Mar-Apr |
|
| Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. | 2004 Nov |
|
| Recent advances in the management of ocular complications of Sjögren's syndrome. | 2005 Jul |
|
| P2 receptors activated by uracil nucleotides--an update. | 2006 |
|
| New approaches in Sjögren's syndrome therapy. | 2007 Mar |
|
| [A molecular marker for dry eye]. | 2007 Mar |
|
| Therapeutic targets in dry eye syndrome. | 2008 Apr |
|
| Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. | 2008 Aug |
|
| Topical application of nucleotides increase lysozyme levels in tears. | 2008 Jun |
|
| Preliminary effects of oral uridine on the ocular surface in dry eye patients. | 2009 Aug |
|
| Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor. | 2011 Jun 23 |
Sample Use Guides
DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium). Usually, instill 1 drop a time 6 times daily.
Route of Administration:
Topical
3% diquafosol tetrasodium had a significant, time-dependent, inhibitory effect on human corneal epithelial cells (HCEC) proliferation and cytotoxicity. HCECs treated with diquafosol detached more from the bottoms of dishes and damaged cells showed degenerative changes, such as, reduced numbers of microvilli, vacuole formation, and chromatin of the nuclear remnant condensed along the nuclear periphery.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:21:22 UTC 2023
by
admin
on
Fri Dec 15 16:21:22 UTC 2023
|
| Record UNII |
X8T9SBH9LL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C78283
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
||
|
FDA ORPHAN DRUG |
116998
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m4661
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
PRIMARY | Merck Index | ||
|
OO-03
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
PRIMARY | |||
|
211427-08-6
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
PRIMARY | |||
|
SUB32869
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
PRIMARY | |||
|
148196
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
PRIMARY | |||
|
X8T9SBH9LL
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
PRIMARY | |||
|
C65437
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
PRIMARY | |||
|
100000126190
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
PRIMARY | |||
|
CHEMBL221326
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
PRIMARY | |||
|
266356-23-4
Created by
admin on Fri Dec 15 16:21:22 UTC 2023 , Edited by admin on Fri Dec 15 16:21:22 UTC 2023
|
SUPERSEDED |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |